Momenta Pharmaceuticals Announces Date of First Quarter 2019 Financial Results Conference Call and Webcast
April 18 2019 - 8:00AM
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology
company focused on discovering and developing novel biologic
therapeutics to treat rare immune-mediated diseases, today
announced that it will release its financial results for the first
quarter ended March 31, 2019 before the U.S. financial markets open
on Thursday, May 2, 2019.
Management will host a conference call on May 2,
2019 at 8:30 a.m. ET to discuss these results and provide an update
on the company. To access the call, please dial (877) 224-9084
(domestic) or (720) 545-0022 (international) prior to the scheduled
conference call time and provide the access code 8949569. A live
webcast of the call will be available on the "Investors" section of
the company's website, www.momentapharma.com. An archived version
of the webcast will be posted on the Momenta website approximately
two hours after the call.
About MomentaMomenta is a
biotechnology company with a validated innovative scientific
platform focused on discovering and developing novel therapeutics
to treat rare, immune-mediated diseases. Momenta’s product
candidate, M281, is a potentially best-in-class anti-FcRn antibody;
M254, is a hyper-sialylated human immunoglobulin (hsIgG) designed
as a high potency alternative to intravenous immunoglobulin (IVIg);
and M230 (CSL730), is a potential first-in-class novel recombinant
Fc multimer being developed in collaboration with CSL. Momenta also
has a focused pipeline of two biosimilar candidates: M923,
Momenta’s wholly-owned proposed biosimilar to HUMIRA®, and M710, a
proposed biosimilar to EYLEA® being developed in collaboration with
Mylan. Momenta’s two FDA-approved complex generic products,
enoxaparin sodium injection and Glatopa® (glatiramer acetate
injection), are marketed by its collaboration partner, Sandoz.
To learn more about Momenta, please visit
www.momentapharma.com, which does not form a part of this press
release.
Momenta’s logo, trademarks, and service marks
are the property of Momenta Pharmaceuticals, Inc. All other trade
names, trademarks, or service marks are property of their
respective owners.
Forward-Looking Statements
Statements in this press release regarding management's future
expectations, beliefs, intentions, goals, strategies, plans or
prospects, are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including but not
limited to statements about the use efficacy, safety, tolerability,
convenience and commercial potential of our product candidates,
including their potential as best-in-class agents. Forward-looking
statements may be identified by words such as "believe,"
"continue," “plan to”, "potential," "will," and other similar words
or expressions, or the negative of these words or similar words or
expressions. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors, including
the risk of the unpredictable nature of early stage development
efforts for our product candidates; safety, efficacy or
tolerability problems with our product candidates; unexpected
adverse clinical trial results; and those referred to under the
section "Risk Factors" in the Company's Annual Report on Form 10-K
for the year ended December 31, 2018 filed with the Securities and
Exchange Commission, as well as other documents that may be filed
by the Company from time to time with the Securities and Exchange
Commission. As a result of such risks, uncertainties and factors,
the Company's actual results may differ materially from any future
results, performance or achievements discussed in or implied by the
forward-looking statements contained herein. The Company is
providing the information in this press release as of this date and
assumes no obligations to update the information included in this
press release or revise any forward-looking statements, whether as
a result of new information, future events or otherwise.
Contact: Patty Eisenhaur Momenta
Pharmaceuticals1-617-395-5189IR@momentapharma.com
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2023 to Apr 2024